MDT-AP-2495
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- new_clusters
- S2
- umap1_2d
- -1.392680003
- umap2_2d
- -8.91116138
- umap1_3d
- -1.830854833
- umap2_3d
- -1.477916573
- umap3_3d
- 4.37290377
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.480
- COAGULATION+0.380
- PANCREAS_BETA_CELLS+0.380
- INFLAMMATORY_RESPONSE+0.370
- INTERFERON_ALPHA_RESPONSE+0.360
- KRAS_SIGNALING_DN+0.360
- ALLOGRAFT_REJECTION+0.350
- INTERFERON_GAMMA_RESPONSE+0.310
- ANGIOGENESIS+0.290
- IL6_JAK_STAT3_SIGNALING+0.280
Top 10 suppressed
- MITOTIC_SPINDLE-0.450
- MYC_TARGETS_V2-0.410
- DNA_REPAIR-0.390
- PROTEIN_SECRETION-0.370
- G2M_CHECKPOINT-0.330
- PI3K_AKT_MTOR_SIGNALING-0.310
- E2F_TARGETS-0.300
- MTORC1_SIGNALING-0.300
- TGF_BETA_SIGNALING-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0747 | Med | Medulloblastoma | 0.953 |
| 2 | SRR1319539 | GTEX | — | 0.930 |
| 3 | MDT-AP-1215 | Med | Medulloblastoma | 0.926 |
| 4 | MDT-AP-2892 | Med | Medulloblastoma | 0.925 |
| 5 | SRR1335707 | GTEX | — | 0.912 |
| 6 | SRR1797289 | — | cohortMD2 | 0.910 |
| 7 | SRR1472150 | GTEX | — | 0.908 |
| 8 | SRR1442666 | GTEX | — | 0.907 |
| 9 | ERR2598337 | fetal | fetal | 0.902 |
| 10 | SRR1440082 | GTEX | — | 0.895 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.480 | Inavolisib | — uncovered |
| COAGULATION | 0.380 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.380 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.360 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.310 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.250 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.220 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.190 | Idelalisib | — uncovered |
| APOPTOSIS | 0.180 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |